MedTrace Logo

Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study

NCT00839449 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2009-09-03

No results posted yet for this study

Summary

Cerebral vasospasm following subarachnoid hemorrhage (SAH) is the most common cause of morbidity and mortality. Recent studies indicate that Rho-kinase play an important role in the occurrence of such cerebral vasospasm. Eicosapentaenoic acid (EPA) inhibits sphingosylphosphorylcholine (SPC)-induced Rho-kinase activation in vitro. So this study examines whether EPA prevents cerebral vasospasm occurrence after SAH in patients.

Conditions

  • Subarachnoid Hemorrhage
  • Cerebral Vasospasm

Interventions

DRUG

Eicosapentaenoic acid ethyl ester

Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.

Sponsors & Collaborators

  • Nakamura Memorial Hospital

    collaborator OTHER

  • Iwate Medical University

    collaborator OTHER

  • Tohoku University

    collaborator OTHER

  • Ootemachi Hospital

    collaborator UNKNOWN

  • Yamaguchi University Hospital

    lead OTHER

Principal Investigators

  • Michiyasu Suzuki, MD, PhD · Yamaguchi University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2008-06-30
Completion
2008-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00839449 on ClinicalTrials.gov